increased DNA damage and apoptosis (7) . In a non-small-cell lung cancer (NSCLC) mouse model, lack of autophagy caused accumulation of dysfunctional mitochondria and dysregulation of lipid catabolism (8) . Besides its impact on tumor cells directly, autophagy inhibition may have anti-tumor effects by modulating the tumor microenvironment (9) . Indeed a recent study from our group demonstrated a cross-talk between stromal and tumor cells in PDAC, where autophagy was required in stromal cells to secrete alanine that was taken up by tumor cells to support growth (10) .
The pro-tumorigenic role of autophagy in tumorigenesis had been studied and validated using genetically engineered mouse models (GEMMs) of multiple other tumors such as melanoma (11) , breast (12) , lung (13), brain (14) , and prostate (15) using conditional knockouts of various autophagy genes. However, with the exception of one study in lung cancer, these have all relied on loss of autophagy during the tumorigenesis process and not acutely in the fully formed tumor (16) . Moreover, the nature of these models allows only for the irreversible loss of autophagy and therefore limits questions that can be asked such as duration of inhibition needed and reversibility of potential toxicities.
Because of autophagy's supporting role in tumor growth, it became a target of interest in cancer treatment. The drug hydroxychloroquine (HCQ) has been tested in multiple clinical trials to assess the efficacy of autophagy inhibition in PDAC and other cancers (17) (18) (19) (20) . While HCQ does inhibit autophagy, it acts at the level of the lysosome, so it will impact additional lysosomal processes (which could actually have additional anti-tumor effects) (21) . Moreover, there are potency issues with the drug, requiring high micromolar levels to inhibit autophagy and observe anti-tumor effects (22, 23) . Interestingly, early data supports that the addition of HCQ to chemotherapy in localized PDAC increases the tumor response (24, 25) .
To overcome some of these obstacles, we sought to create a model where autophagy could be acutely inhibited in a reversible fashion in a fully formed tumor. This would be akin to the therapeutic scenario, much in the way a pharmacological inhibitor works. As selective and potent inhibitors targeted to the early phases of autophagy are still in various phases of development, we took a genetic approach to model such inhibition paradigms using a previously identified dominant negative mutant of Atg4B that was reported to effectively inhibit autophagy (26) . In this study, we took advantage of this dominant negative mutant to generate an inducible mouse model of autophagy inhibition and evaluated the effectiveness of autophagy inhibition in treating PDAC, as well as further explored the mechanisms of autophagy in supporting tumor
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Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/2159-8290.CD- growth. Indeed, we demonstrated striking tumor responses in a treatment refractory PDAC GEMM, including some complete responses. Importantly, the innovative design of the model allowed us to demonstrate that autophagy inhibition suppresses tumor growth via tumor cell intrinsic as well as extrinsic factors.
Results

Generating an inducible mouse model of autophagy inhibition
Autophagy is a multistage process and the formation of the autophagosome is an essential step to package different cargo for autophagic degradation. To form the autophagosome membrane, a cysteine protease --Atg4B, is required to conjugate LC3 with phosphatidylethanolamine (PE) and delipidate LC3-II after lysosome degradation. An enzymatically inactive mutant, Atg4B C74A , was previously found to be able to sequester free LC3 in vitro and therefore act as a dominant negative inhibitor of autophagy degradation (26) . We developed a transgenic mouse line that carries the mSt-Atg4B
C74A gene under the control of TetOn cassette (hereafter referred to as Atg4B CA ) ( Figure S1 ). The dominant negative Atg4B C74A mutant was fused with an mStrawberry fluorescent marker, allowing its expression to be easily tracked. The reverse tetracyclinecontrolled transactivator (rtTA) at the Rosa26 locus was preceded by a stopper cassette allowing the expression to be controlled via cre-recombinase. Therefore, the combination of TetOn and LoxP expression systems allowed the expression of Atg4B C74A to be temporally controlled and spatially restricted ( Figure 1A ).
We crossed the Atg4B CA (either one or two copies +; ++); Rosa-rtTA LSL transgenic mouse to a well-established pancreatic cancer genetically engineered mouse model (GEMM): LSL-
Kras
G12D
, p53
To determine the efficiency of autophagy inhibition, we first generated cell lines derived from tumors to assess the ability of the Atg4B CA to inhibit autophagic flux in vitro. As shown in Figure 1B , treatment of cells with doxycycline (Dox) resulted in expression of the Atg4B CA as indicated by the mStrawberry fluorescence. Expression greater levels of the Atg4B CA expression and showed more autophagy inhibition ( Figure 1E and S2A).
We next tested the tight regulation of Atg4B CA expression by showing dependence on the required alleles and the presence of Dox ( Figure 1F ). In contrast to the control groups, the two test groups treated with Dox: Atg4B CA+ and Atg4B CA++ that were expected to express Atg4B CA allele stained positive for mStrawberry ( Figure 1F ). Consistent with the in vitro data, potent autophagy inhibition by expression of Atg4B CA was confirmed in vivo. LC3 puncta were present in the two control groups (not expressing Atg4B We also examined autophagosome formation at ultrastructural level by electron microscopy. As shown in Figure 1H , most double membrane vesicular structures were closed in Atg4B-tumor 
Inhibition of autophagy decreases growth of fully formed PDAC
To evaluate the effect of autophagy inhibition on tumor growth, we used high-resolution ultrasound imaging to identify PDAC and follow their growth ( Figure S3A ). We generated four groups of mice that did not express Atg4B CA due to lack of the genetic alleles or Dox exposure.
The four negative control cohorts of mice did not express Atg4B CA and showed no significant differences in tumor growth or tumor specific survival ( Figure S3B -C) . Thus, for comparison we combined all mice not expressing Atg4B CA in one group denoted as Atg4B-from here forward.
To study how autophagy inhibition affected established PDAC growth, we first allowed tumors to form and measured volume by serial high resolution ultrasound. During the study, we didn't observe significant effect of Doxycycline food or autophagy inhibition on weight of tumor-bearing mice ( Figure S3D and E (Figure 2A and B) . However, after an initial delay in tumor progression all tumors resumed growth and mice finally succumbed to tumor burden. An assessment of these tumors at endpoint revealed that all mice (n=10) at the end of the study had lost expression of the However, despite these dramatic responses there was no significant increase of survival in the Atg4B CA++ group compared to control group (Fig 2D) . After examining the Atg4B CA++ tumors at endpoint, we found that all four mice that had died within 3 weeks showed histological disruption of the normal pancreas architecture with significant areas of metaplasia, which were composed of abnormal ductal-like, mucin-rich cells stained positive for CK19 ( Figure S5A ). Additionally, the pancreata showed loss of β-islets in both the Atg4B CA++ and control mice likely due to tumor replacement of normal pancreata ( Figure S5B ). Serum insulin levels were not significantly changed in Atg4B CA++ mice compared to Atg4B-mice, indicating there was not likely frank diabetes. Consistent with this, there was only minimal expression of Atg4B CA++ in the β-islets ( Figure S5B ) due to differences in expression of the allele between the tissues. We further stained for amylase and found a dramatic loss of normal acinar cells, indicating a profound disruption of the exocrine pancreas in the Atg4B CA++ expressing tumor-bearing mice ( Figure   S5C We then analyzed proliferation in tumors by measuring Ki67 expression. Consistent with the decreased growth, we found there was a significant reduction of proliferating cells in Atg4B CA+ and Atg4B
CA++ groups ( Figure 2H ).
Using a Kras-driven lung GEMM, we were able to extend these findings to lung cancer by monitoring tumor growth with magnetic resonance imaging (MRI) ( Figure S6A ). Once tumor was identified, mice were randomly assigned to Dox diet as in the PDAC studies. Similar to the PDAC model, we noticed a significant growth deficit in Atg4B CA+ mice ( Figure S6B ). Atg4B CA+ tumors showed less Ki67+ cells compared to Atg4B-tumors, indicating less proliferation ( Figure   S6C ). However, unlike PDAC, lung tumors did not show significant increases in apoptosis. This may reflect the unique PDAC microenvironment which is known to be poorly perfused, hypoxic, and nutrient poor (27) .
Cell intrinsic and extrinsic factors impact tumor growth in response to autophagy inhibition
Previous work from our group has shown that in various systems that autophagy supports PDAC tumor cell growth through effects on the tumor cell itself (2). More recently, we identified that autophagy in the stromal compartment was critical for a metabolic cross-talk to fuel tumor cells (10) . Therefore, we set out to explore the contributions of autophagy to various aspects of 
Stromal Autophagy and PDAC growth
We had previously demonstrated through co-culture and co-injection studies that autophagy inhibition in the stroma can influence growth of the PDAC tumor cells through the secretion of amino acids (10) . Figure S9A ). Thus we did not observe any behavior abnormalities or premature death as had been reported in the Atg7 adult knockout mice ( Figure S9B ). There was only one mouse from the Atg4B CA++ group that died earlier than 30 weeks due to a hernia. Based on the H&E histology examination of all mice older than 52 weeks, no significant difference was found among all groups. Overall, in this model, the whole-body inhibition of autophagy in a mosaic fashion did not appear to have any grossly detrimental effect on normal organs.
Next, we wanted to distinguish the cell autonomous effect vs. non-cell autonomous effects of autophagy inhibition on tumor seeding efficiency and growth. We used mouse tumor cell lines harvested from primary tumors and performed orthotopic injection into MHC H2 matched hosts (50% B6 and 50% FVB/N). First, we injected Atg4B CA++ tumors into Atg4B CA++ mice or Atg4B-mice on normal or Dox diets as shown in Figure 4A . Three groups of mice were generated to allow a pairwise comparison on the effect of autophagy inhibition in tumor cells or whole body:
Atg4B-tumors in Atg4B-mice (BD-TU-, n=13), Atg4B CA++ tumors in Atg4B-mice (BD-TU++, n=11) and Atg4B CA++ tumors in Atg4B++ mice (BD++ TU++, n=16). After 3 weeks, both groups that had Atg4B CA++ expressed in the tumor (either BD-or BD++) showed significant difference in the development of tumors compared to group where there was no autophagy inhibition in either the tumor or whole body (BD-TU-) ( Figure 4B ). These results indicate that cell autonomous autophagy inhibition plays a major role in controlling tumor seeding efficiency. Furthermore, tumor growth rate was unaffected by the whole-body expression and was determined predominantly by cell intrinsic expression of Atg4B CA++ ( Figure 4C ). However, we noticed that although the ultimate ability to form tumors was determined by the expression of Atg4B CA in the tumor itself, there was an early trend of delayed tumor formation in mice with whole body expression of Atg4B CA++ ( Figure 4B) . Indeed, at the earliest time-points the seeding efficiency was lowest in BD++ TU++ group where both body and tumor cells had autophagy inhibition ( Figure 4B ). To further explore the whole-body effect of autophagy inhibition on tumor take, we injected Atg4B-cell lines into Atg4B CA++ , Rosa-rtTA LSL , Ubc-ERT/Cre + mice on either normal or Dox diet ( Figure 4D ). Two groups were generated to understand the non-tumor cell autonomous effects of autophagy inhibition: Atg4B-tumors in Atg4B-mice (BD-TU-, n=15) and Atg4B-tumors in Atg4B CA++ mice (BD++ TU-, n=16). We found there was indeed a significantly delayed
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tumor take in the BD++ group ( Figure 4E ). Once a tumor successfully established, there was no significant difference in tumor growth between Atg4B-and Atg4B CA++ mice ( Figure 4F ).
Importantly, Dox alone did not impact tumor seeding ( Figure S10A ).
In line with our previous work demonstrating the importance of stellate cell autophagy in supporting tumor growth, we found a negative selection against the expression of the Atg4B CA in stellate cells at the endpoint of the experiment when tumors have formed (Fig S10B) . In contrast, the Atg4B CA was expressed in stellate cells in normal pancreas (Fig S10C) . This negative selection in the tumor supports the concept that stellate cell autophagy is important for tumor growth in the pancreas and consistent with our prior work demonstrating an autophagydependent metabolic cross-talk (10).
Discussion
In this study, we addressed several questions regarding the inhibition of autophagy as a therapeutic target in pancreatic cancer. While hydroxychloroquine (HCQ) is being tested in PDAC as well as multiple other cancers and has shown some preliminary successes (30), the drug not only inhibits autophagy but also inhibits other aspects of lysosomal scavenging. Therefore, it is not possible to specifically assess the contributions of its anti-autophagy effects.
In addition, there are potency issues with HCQ that may limit its utility (31) . Together, these limitations require the development of more potent and specific autophagy inhibitors to rigorously test this approach in the clinic. Such inhibitors are in various phases of development.
In the interim, the inducible Atg4B CA model allowed us to address several fundamental questions that are critical to optimally bring autophagy inhibition forward to the clinic. Firstly, it allowed us to model the impact of potent inhibition at the early part of the autophagic process in fully formed tumors. Secondly, the inducible nature of the model allowed us to test the impact of intermittent autophagy inhibition. In essence, we have been able to utilize this new model to create a "genetic drug". Combining this model with a pancreatic cancer GEMM, we have shown that these tumors show robust responses to autophagy inhibition. Indeed, our data also suggests that intermittent dosing of future autophagy inhibitors could be a viable strategy to create a therapeutic index. Although the mosaic nature of the model limited our ability to assess toxicity of whole body inhibition of autophagy, the lack of observed toxicity and histological damage of tissues suggests that autophagy inhibitors may be tolerated by patients when dosed appropriately. It is important to note that the Atg4B CA transgene did not express in the CNS, which may also explain the lack of toxicity in our model, as CNS toxicity is a major cause of
Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/2159-8290.CD-17-0952 morbidity in previous studies (16) . Given the relative ease of designing small molecules that cannot cross the blood-brain-barrier (BBB), future autophagy inhibitors may be designed with favorable toxicity profiles. Such an approach was taken with newly designed glutaminase inhibitors (32) , where the known CNS toxicity was mitigated by limiting BBB penetration.
Using this new model, we have also been able to address some debated biological questions regarding the role of autophagy in pancreatic cancer. In particular, it has allowed us to deconvolute the cell autonomous (impacts the tumor cell directly) and non-cell autonomous (impacts tumor growth through its role on other cell-types) and show that both are relevant to its role in tumor promotion ( Figure 4G) . Similar to what we have previously shown, autophagy inhibition in the context of tumor initiating mutations (Kras mutation and p53 loss) can predispose to metaplasia and pre-malignant lesions (PanIN). This is highlighted in the genetic model where the entire pancreas has these oncogenic and tumor suppressor mutations, a situation that would not occur in the context of the human disease. Indeed, we do not see these marked histological changes in the context of autophagy inhibition in pancreata where oncogenic Kras is not expressed. Therefore, we believe that this will not likely be a significant issue in the therapeutic situation in patients where these genetic lesions are restricted to neoplastic tissue. While this "model effect" is not likely a concern for therapy (treating patients with established cancer), it might suggest that using autophagy inhibitors chronically as a chemopreventative strategy could be an issue.
One of the novel findings in this study was that the impact on tumor regression, when autophagy was inhibited in the tumor itself, was partially mediated by macrophages. Indeed, we could significantly inhibit the responses to the Atg4B CA by depleting macrophages in the mouse.
As macrophage modulation is being tested in PDAC as a therapeutic approach (28, 33) , whether combining such agents with autophagy inhibitors would be beneficial remains to be determined.
We speculate that autophagy could regulate macrophage infiltration by degradation of inflammation-regulators, as well as directly affecting cytokine secretion as has been shown previously (34) . The fact that autophagy inhibition systemically impacts tumor engraftment, supports the additional contribution of non-cell autonomous effects in the efficacy of autophagy inhibition. One likely explanation for this effect is the autophagy-dependent metabolic cross-talk between the tumor cells and the stroma previously described by our group. Although, we cannot rule out the contribution of other systemic effects of autophagy inhibition such as potentially heightened immune surveillance as an example. However, the fact that there appears to be stromal and immunological mediators that contribute to the anti-tumor effects of
Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/2159-8290.CD-17-0952 autophagy inhibition further supports both a cell autonomous and non-autonomous protumorigenic role for autophagy in PDAC and provides the strongest evidence to date that acute and potent inhibition of autophagy is effective in treating this disease in mouse models.
One limitation of the study is that we haven't yet assessed the impact of autophagy inhibition in different host cell types in the PDAC microenvironment other than stellate cells (10) . Future studies will define the broader role of autophagy in distinct cell populations and how these influence tumor growth. Lastly, future studies will develop rationally designed therapeutic combinations with autophagy inhibition to guide trials with newer autophagy inhibitors.
Materials and Methods
Construction of targeting vector and screening of ES cells
The mStrawberry-Atg4B C74A cDNA fragment was cloned from the mStrawberry-Atg4B Ubc-ERT/Cre + mice (Jackson Laboratory, Bar Harbor, ME) (40) were backcrossed to B6
Measurement of tumor volume by ultrasound
All mice were kept on a normal diet and screened weekly for tumor presence upon reaching 6 weeks of age. Once a tumor was detected, the mouse was randomly assigned to either the control group by being kept on the normal diet or treatment group by being switched to doxycycline diet (625 mg/kg Dox). Tumors were at least 2mm in diameter prior to enrollment . Motion artifacts were minimized by application of cardiac and respiratory gating to all MRI studies. All animals were scanned by using the described settings and parameters. Tumor volume (mm 3 ) per animal was quantified by manual segmentation of the visible lung opacities present in each axial image sequence (a maximum of 10 consecutive scans were evaluated per mouse) to calculate tumor volumes using 3D Slicer (version 3.6.3) as described previously (41) .
Immunohistochemistry
All samples were harvested for histology analysis at end-point unless otherwise specified.
Samples resected from mice were fixed overnight in formalin, and then stored in 70% EtOH
Research. by using light Microscope Leica DM2000 with camera. LC3 staining was modified with additional steps using TSA biotin system following manufacturer's instruction (NEL700A001KT, PerkinElmer, MA). Arginase 1 (1:100, NBP1-32731, Novus Biological, CO) stained IHC slides were scanned with 20x objective using Leica SCN400F whole-slide scanner, the DAB and hematoxylin stained area were calculated using ImageJ and analyzed using GraphPad Prism 7.03.
Immunofluorescence (IF)
Cells were grown on round coverslips in 12-well plate and fixed with 4% formaldehyde for 15 minutes. Fixed cells were blocked with 5% BSA / 0.3% Triton X-100 in PBS for 1 hour, and then incubated with primary antibody diluted in 1% BSA / 0.3% Triton X-100 in PBS overnight at 4°C. using Leica DM6B. The ratio of total area of fluorescence was calculated and normalized with the total area of DAPI using ImageJ.
Western
Proteins were extracted with RIPA buffer and separated on 4-12% stacking SDS-PAGE gel, and then transferred to PVDF membrane (Biorad). Membranes were blocked with 5% non-fat milk and then incubated with the primary antibody overnight at 4°C. Following TBST washing, membranes were incubated with peroxidase-conjugated secondary antibody for 1 hour and exposed on film using the enhanced chemiluminescence (ECL) detection system (Thermo Scientific). Antibodies used were: RFP rabbit polyclonal (1:1000, 600-401-379, Rockland, PA); Cleaved-Caspase 3 rabbit polyclonal (1:500, D175, Cell signaling); LC3B (1:500, NB600-1384, Novus Biological), and β-Actin (1:3000, A2066, Sigma, MO).
Serum insulin measurement
Serum was collected at harvest, where whole blood was allowed to clot then after centrifugation the supernatant was carefully collected, aliquot and stored in -80°C. Insulin level was measured using mouse insulin Elisa kit (10-1247-01, Mercodia, Sweden) following manufacturer's instruction.
Colony assay
Cells were pretreated with or without doxycycline for 7 days before plating into 6-well plates. 500 cells per well were plated in growth medium with 10% FBS with or without 2 µg/ml doxycycline. After 6 days, cells were fixed in 80% methanol and stained with 0.2% crystal violet and colonies were counted. The surviving fraction was calculated using the plating efficiency.
Soft agar assay
Each cell line was plated in triplicate in 6-well plate. 3 ml medium with 1% agar (Difco 214200, BD, NJ) was used as bottom gel. After the bottom layer solidified, 10 4 cells suspended in 2 ml medium with 0.4% agar were poured on bottom gel. After 2 weeks, colonies were stained with p-iodonitrotetrazonium violet (I-8377, Sigma, MO). Number of colonies was counted from pictures taken at low power lens of microscopy. Size of colonies was analyzed by Image-J software.
Cell culture
on January Overall survival events included death as defined by protocol with censoring for alive at last follow-up. Survival plots were generated using the Kaplan-Meier method. The log-rank test was used to compare survival distributions between groups. The seeding efficiency of mice with orthotopic injection was compared using a Fisher's exact test. Statistical analyses were performed using with Prism 7 (GraphPad Software). 
